AK Medical Holdings Ltd. (1789) AI Stock Analysis

• Market Cap: HK$6.71B
• Dividend Yield: 1.2%
• Average Volume (3M): 4.18M
• Price to Earnings (P/E): 22.5
• Beta (1Y): 1.18
• Revenue Growth: 20.19%
• EPS Growth: 45.54%
• Country: HK
• Employees: 950
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Devices
• EPS (TTM): 0.13
• Shares Outstanding: 1,122,695,800
• 10 Day Avg. Volume: 4,322,099
• 30 Day Avg. Volume: 4,184,210
• PEG Ratio: 0.50
• Price to Book (P/B): 2.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 369.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$5.50
• Price Target Upside: -8.18% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 75 Outperform
• Price Target: HK$6.50 ▲(8.51%Upside)

AK Medical Holdings Ltd. is financially strong with impressive revenue and profit growth, supported by a robust balance sheet. However, inconsistent cash flow management presents a risk. Moderate technical indicators and valuation metrics suggest limited immediate upside potential.

AK Medical Holdings Ltd. Business Overview & Revenue Model

Company Description

AK Medical Holdings Limited, an investment holding company, designs, develops, produces, and markets orthopedic joint implants and related products under the AK Medical brand in China and internationally. It offers knee, hip, and spine replacement implants; and 3D-printed products, such as 3D-printed hip replacement implants, 3D-printed artificial vertebral bodies, and 3D-printed spinal interbody cages. The company also distributes third party orthopedic products; and manufactures surgical instruments and medical irrigators. Its principal customers include distributors, hospitals, physicians and surgeons, and patients. The company was founded in 2003 and is headquartered in Beijing, the People's Republic of China. AK Medical Holdings Limited is a subsidiary of Ximalaya Limited.

How the Company Makes Money

AK Medical Holdings Ltd. generates revenue primarily through the sale of its orthopedic products, including joint prostheses and surgical instruments, to hospitals, clinics, and healthcare providers. The company's revenue streams are bolstered by its strong emphasis on innovation and the use of advanced technologies such as 3D printing, which allows for the creation of highly customized implants tailored to individual patient needs. Additionally, AK Medical may engage in strategic partnerships and collaborations with healthcare institutions and research organizations to expand its market reach and enhance its product offerings. These partnerships can provide additional revenue opportunities through joint development projects and shared resources.

AK Medical Holdings Ltd. Financial Statement Overview

Summary

AK Medical Holdings Ltd. displays strong revenue growth and profitability. The balance sheet is robust with low leverage and high equity. However, inconsistent cash flow management needs improvement to support growth initiatives.

Income Statement

AK Medical Holdings Ltd. has demonstrated strong revenue growth over the years, with a significant increase from 2023 to 2024. The gross profit margin has remained healthy, with a slight improvement. Net profit margin has also seen an upward trend, indicating efficient cost management. EBIT and EBITDA margins are stable, showcasing effective operational management.

Balance Sheet

The company maintains a robust balance sheet with a low debt-to-equity ratio, indicating low financial leverage. A high equity ratio reflects strong capitalization. The return on equity is solid, showcasing effective use of shareholder funds. Overall, the company is financially stable with a strong equity base and manageable liabilities.

Cash Flow

Cash flow from operations has been inconsistent, with a significant drop in the latest year. The free cash flow has also been volatile, reflecting potential challenges in managing capital expenditures and investments. However, the company's ability to generate operating cash flow relative to net income indicates potential for improvement.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.35B	1.09B	1.05B	761.44M	1.04B
Gross Profit	808.19M	674.49M	636.43M	499.19M	714.53M
EBITDA	371.66M	323.34M	322.87M	184.33M	438.41M
Net Income	273.93M	182.10M	204.77M	92.62M	314.01M
Balance Sheet
Total Assets	3.34B	3.00B	2.77B	2.61B	2.53B
Cash, Cash Equivalents and Short-Term Investments	1.05B	726.67M	1.04B	841.13M	901.49M
Total Debt	99.39M	84.20M	38.78M	41.56M	26.85M
Total Liabilities	697.21M	611.12M	530.73M	573.73M	484.13M
Stockholders Equity	2.64B	2.39B	2.24B	2.03B	2.04B
Cash Flow
Free Cash Flow	289.11M	-162.14M	121.20M	100.39M	115.47M
Operating Cash Flow	451.07M	33.94M	242.92M	176.62M	205.26M
Investing Cash Flow	-393.35M	-318.15M	-82.29M	-297.10M	-356.41M
Financing Cash Flow	-39.43M	-14.02M	-36.80M	-100.70M	611.74M

AK Medical Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1789, the sentiment is Positive. The current price of 5.99 is below the 20-day moving average (MA) of 6.00, above the 50-day MA of 5.80, and above the 200-day MA of 5.10, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 53.17 is Neutral, neither overbought nor oversold. The STOCH value of 30.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1789.

AK Medical Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1789	75 Outperform	HK$6.71B	22.50	10.92%	1.20%	20.19%	45.54%
Sector *	60 Neutral	HK$15.27B	5.60	-7.43%	4.22%	11.60%	-21.06%
4WO		€461.36M	―	-10.43%	―	―	―
818		€737.30M	53.77	3.22%	―	―	―
1302	72 Outperform	HK$8.77B	37.25	6.49%	―	0.87%	-18.05%
1858	65 Neutral	HK$6.53B	32.03	4.39%	3.18%	-32.05%	-54.47%
6606		HK$6.47B	―		―	―	―

AK Medical Holdings Ltd. Corporate Events

AK Medical Holdings Announces Change in Share Registrar

AK Medical Holdings Limited has announced a change in its Hong Kong Share Registrar and Transfer Office, effective from August 1, 2025. The new registrar will be Tricor Investor Services Limited, and all applications for registration and transfer of shares should be directed to them from this date. This change is part of the company’s ongoing efforts to streamline its operations and improve shareholder services.

The most recent analyst rating on (HK:1789) stock is a Buy with a HK$5.27 price target. To see the full list of analyst forecasts on AK Medical Holdings Ltd. stock, see the HK:1789 Stock Forecast page.

AK Medical Holdings Ltd. Updates Nomination Committee to Enhance Governance

AK Medical Holdings Ltd. announced changes in its Nomination Committee, effective June 25, 2025, in response to amendments in the Listing Rules and Corporate Governance Code. These changes include the appointment of Dr. Li Shu Wing David as the new chairman and Ms. Zhang Bin as a member, aiming to enhance board effectiveness and diversity, thereby strengthening corporate governance practices.

The most recent analyst rating on (HK:1789) stock is a Buy with a HK$5.27 price target. To see the full list of analyst forecasts on AK Medical Holdings Ltd. stock, see the HK:1789 Stock Forecast page.

AK Medical Holdings Ltd. Announces Successful AGM Resolutions

AK Medical Holdings Ltd. announced the results of its Annual General Meeting held on June 18, 2025, where all proposed resolutions were passed. Key decisions included the approval of the audited financial statements for 2024, the declaration of a final dividend, re-election of directors, re-appointment of KPMG as auditors, and granting mandates to the directors for share repurchase and issuance. These resolutions reflect the company’s continued focus on financial transparency, shareholder returns, and strategic flexibility in managing its share capital.

The most recent analyst rating on (HK:1789) stock is a Buy with a HK$5.27 price target. To see the full list of analyst forecasts on AK Medical Holdings Ltd. stock, see the HK:1789 Stock Forecast page.

AK Medical Holdings Announces 2025 AGM and Key Resolutions

AK Medical Holdings Ltd. has announced its upcoming annual general meeting, scheduled for June 18, 2025, in Beijing, China. Key agenda items include the approval of financial statements, declaration of a final dividend, re-election of directors, and the reappointment of KPMG as auditors. Additionally, the company seeks shareholder approval for mandates to repurchase shares and issue additional shares, which could impact its market operations and shareholder value.